测定 HIV 感染患者的血浆和细胞内拉替拉韦浓度。
Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection.
机构信息
Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
出版信息
AIDS. 2012 Nov 13;26(17):2257-9. doi: 10.1097/QAD.0b013e328359a978.
Paired plasma and intracellular samples were obtained from 12 HIV-infected adults taking raltegravir twice daily (b.i.d.), and after switching to once daily. With b.i.d. dosing, no plasma trough concentrations were below the IC95, in contrast to 33% for once daily dosing. Fifty percent of the once daily group had intracellular trough concentrations below the inhibitory concentration 95 (IC95), 25% in the b.i.d. group. Lower plasma and intracellular concentrations may contribute to inferior virologic suppression rates observed with once daily raltegravir dosing.
从 12 名每日服用两次利匹韦林（b.i.d.）的 HIV 感染成年人和每日一次转换后的患者中获得配对的血浆和细胞内样本。与每日一次给药相比，每日两次给药时没有血浆谷浓度低于 IC95，而每日一次给药时为 33%。在每日一次给药组中，有 50%的细胞内谷浓度低于 95%的抑制浓度（IC95），而在每日两次给药组中为 25%。较低的血浆和细胞内浓度可能导致每日一次利匹韦林给药的病毒学抑制率较差。
Zotero 插件